The WTA will mandate genetic sex testing for all players on its tour, effective this Tuesday. Under the new women’s eligibility policy, competitors must submit a cheek swab, blood or saliva sample to detect the presence of the SRY gene, a Y‑chromosome marker that drives male traits.

Players will be tested only once in their lifetime; a negative result, confirming no SRY gene, will allow participation. A positive outcome triggers further medical assessment before any competition is granted. Refusal to test subjects players to disciplinary action per a signed declaration.

The update replaces the 2024 rule that allowed transgender women with testosterone levels below 2.5 nmol/L over two years. No trans women currently compete on the WTA tour. The board said the revision promotes equal opportunity and fair play, citing a 1975 policy review and consultations with members.

The change follows World Athletics’ 2025 gene‑testing mandate and World Boxing’s 2025 adoption of the SRY test. The WTA emphasises sensitivity, dignity and respectful implementation of the new biological‑sex‑based criteria.